Status:
COMPLETED
Fludeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) Cervical Heterogenity Imaging Study
Lead Sponsor:
Washington University School of Medicine
Conditions:
Cervical Cancer
Eligibility:
FEMALE
18-100 years
Phase:
NA
Brief Summary
Rationale: Diagnostic procedures, such as positron emission tomography (PET) using fluorodeoxyglucose (FDG), may help determine response to standard cancer therapy in patients with cervical cancer Th...
Eligibility Criteria
Inclusion
- Biopsy-proven cervical cancer. (FIGO stage-Ib2-IVa)
- Age ≥ 18
- Able to receive chemoradiation therapy with Cisplatin.
- Non-pregnant status in women of childbearing potential.
- No other active cancer at the time of diagnosis of cervical cancer Patients cannot have received treatment for any malignancy, with the exception of non-melanoma skin cancer, in the past 5 years.
- Patients with distant metastatic disease are eligible provided the estimated survival of the patient is at least 1 year.
- Scheduled to undergo or have already undergone FDG-PET/CT imaging for clinical staging of cervical cancer at Barnes-Jewish Hospital Clinical PET Facility on a Biograph 40 PET/CT scanner
- Able to give informed consent
Exclusion
- Age \< 18
- Patients with a known active malignancy other than cervical carcinoma.
- Pregnant and breastfeeding patients.
- Subjects whose tumors are not FDG avid on baseline standard of care FDG-PET/CT imaging
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2016
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00907140
Start Date
August 1 2008
End Date
December 1 2016
Last Update
January 20 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Washington University at St. Louis
St Louis, Missouri, United States, 63110